Locations

Study

Alzheimer’s Tau Protein Study

Help Shape Future Treatments

Tau Protein-Targeting Antibodies

The next generation of drugs in the battle against Alzheimer’s disease may possibly be tau protein-targeting antibodies. These proteins—which normally contribute to the health of neurons in the brain—are impaired by Alzheimer’s. This damage in key brain regions disrupts the brain’s circuits and networks responsible for various cognitive functions, possibly accelerating Alzheimer’s.

A new trial is seeking candidates to test one of the first of these potential tau protein-targeting treatments. Laboratory tests identified a specific antibody delivered intravenously inhibited the spread of tau tangles by more than 70%. The trial aims to measure the safety and tolerability of that antibody.

 

Who is eligible?

You may qualify for this study if:

  • You are 50-90 years old.
  • You have a clinical diagnosis of early-Alzheimer's.
  • Or you have evidence of pathology consistent with Alzheimer's disease.

Sign Up

Schedule Your Assessment

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.

Get More Information

Your contact information

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is for validation purposes and should be left unchanged.

Locations supporting this study